Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/31961
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAbtahi, Shahab-
dc.contributor.authorBurden, Andrea M.-
dc.contributor.authorGEUSENS, Piet-
dc.contributor.authorvan Staa, Tjeerd-
dc.contributor.authorVAN DEN BERGH, Joop-
dc.contributor.authorde Vries, Frank-
dc.date.accessioned2020-09-24T12:04:20Z-
dc.date.available2020-09-24T12:04:20Z-
dc.date.issued2020-
dc.date.submitted2020-09-01T13:28:56Z-
dc.identifier.citationJournal of the American Medical Directors Association, 21 (6) , p. 811 -816-
dc.identifier.issn1525-8610-
dc.identifier.urihttp://hdl.handle.net/1942/31961-
dc.description.abstractBisphosphonates (BPs) might have extra benefits in reducing mortality because of their anti-atherosclerotic effects, but studies reported conflicting results. We investigated the association between oral BP use and mortality risk following a major osteoporotic fracture (MOF) in the United Kingdom.-
dc.language.isoen-
dc.publisherELSEVIER SCIENCE INC-
dc.rights2019 AMDA - The Society for Post-Acute and Long-Term Care Medicine.-
dc.subject.otherIntima-Media Thickness-
dc.subject.otherHip Fracture-
dc.subject.otherZoledronic Acid-
dc.subject.otherAlendronate-
dc.subject.otherDisease-
dc.subject.otherWomen-
dc.subject.otherCalcification-
dc.subject.otherMetaanalysis-
dc.subject.otherPrevention-
dc.subject.otherMen-
dc.titleThe Association of Oral Bisphosphonate Use With Mortality Risk Following a Major Osteoporotic Fracture in the United Kingdom: Population -Based Cohort Study-
dc.typeJournal Contribution-
dc.identifier.epage816-
dc.identifier.issue6-
dc.identifier.spage811-
dc.identifier.volume21-
local.format.pages6-
local.bibliographicCitation.jcatA1-
dc.description.notesde Vries, F (corresponding author), Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Univ Weg 99, NL-3584 CG Utrecht, Netherlands.-
dc.description.notesf.devries@uu.nl-
dc.description.otherde Vries, F (corresponding author), Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Univ Weg 99, NL-3584 CG Utrecht, Netherlands. f.devries@uu.nl-
local.publisher.placeSTE 800, 230 PARK AVE, NEW YORK, NY 10169 USA-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.identifier.doi10.1016/j.jamda.2019.11.003-
dc.identifier.pmid31839557-
dc.identifier.isiWOS:000542142700017-
dc.contributor.orcidvan den Bergh, Joop/0000-0003-3984-2232; Abtahi,-
dc.contributor.orcidShahab/0000-0003-0482-5563; /0000-0001-7082-8530; de Vries,-
dc.contributor.orcidFrank/0000-0003-3837-8319-
dc.identifier.eissn1538-9375-
local.provider.typewosris-
local.uhasselt.uhpubyes-
local.description.affiliation[Abtahi, Shahab; Burden, Andrea M.; de Vries, Frank] Maastricht Univ, Dept Clin Pharm & Toxicol, Med Ctr, Maastricht, Netherlands.-
local.description.affiliation[Abtahi, Shahab; de Vries, Frank] Maastricht Univ, Cardiovasc Res Inst Maastricht CARIM, Maastricht, Netherlands.-
local.description.affiliation[Abtahi, Shahab; Burden, Andrea M.; Geusens, Piet] Maastricht Univ, Care & Publ Hlth Res Inst CAPHRI, Maastricht, Netherlands.-
local.description.affiliation[Abtahi, Shahab; Burden, Andrea M.; van Staa, Tjeerd; de Vries, Frank] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Univ Weg 99, NL-3584 CG Utrecht, Netherlands.-
local.description.affiliation[Burden, Andrea M.] Swiss Fed Inst Technol, Dept Chem & Appl Biosci, Inst Pharmaceut Sci, Zurich, Switzerland.-
local.description.affiliation[van den Bergh, Joop P.] Maastricht Univ, NUTRIM Sch Nutr & Translat Res Metab, Maastricht, Netherlands.-
local.description.affiliation[van den Bergh, Joop P.] Maastricht Univ, Dept Internal Med, Div Rheumatol, Med Ctr, Maastricht, Netherlands.-
local.description.affiliation[van den Bergh, Joop P.] VieCuri Med Ctr, Dept Internal Med, Venlo, Netherlands.-
local.description.affiliation[van den Bergh, Joop P.] Hasselt Univ, Fac Med & Life Sci, Hasselt, Belgium.-
local.description.affiliation[van Staa, Tjeerd] Univ Manchester, Div Informat Imaging & Data Sci, Manchester Acad Hlth Sci Ctr, Sch Hlth Sci,Fac Biol Med & Hlth,Ctr Hlth Informa, Manchester, Lancs, England.-
local.description.affiliation[de Vries, Frank] Southampton Gen Hosp, MRC Epidemiol Lifecourse Unit, Southampton, Hants, England.-
local.uhasselt.internationalyes-
item.contributorAbtahi, Shahab-
item.contributorBurden, Andrea M.-
item.contributorGEUSENS, Piet-
item.contributorvan Staa, Tjeerd-
item.contributorVAN DEN BERGH, Joop-
item.contributorde Vries, Frank-
item.fullcitationAbtahi, Shahab; Burden, Andrea M.; GEUSENS, Piet; van Staa, Tjeerd; VAN DEN BERGH, Joop & de Vries, Frank (2020) The Association of Oral Bisphosphonate Use With Mortality Risk Following a Major Osteoporotic Fracture in the United Kingdom: Population -Based Cohort Study. In: Journal of the American Medical Directors Association, 21 (6) , p. 811 -816.-
item.accessRightsRestricted Access-
item.fulltextWith Fulltext-
item.validationecoom 2021-
crisitem.journal.issn1525-8610-
crisitem.journal.eissn1538-9375-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
The Association of Oral Bisphosphonate .pdf
  Restricted Access		Published version293.39 kBAdobe PDFView/Open    Request a copy
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.